| Application no. and date | 21715306.3 (espacenet) (Federated) (European Patent Register), 20210322 | | Patent/reg. no. and date | DK/EP 4125881, 20240724 | | Publication date | 20230208 | | Priority no. and date | GB 202004209, 20200323, GB 202009574, 20200623, US 202017113416, 20201207 | | EP pub. no. and date |
EP 4125881 20230208 | | Effective date | | | Applicant/owner | Vicore Pharma AB, Kornhamnstorg 53
111 27 Stockholm, SE | | Applicant ref. no. | | | Inventor | DALSGAARD, Carl-Johan, Kornhamnstorg 53
111 27 Stockholm, SE,
RAUD, Johan, Kornhamnstorg 53
111 27 Stockholm, SE,
BATTA, Rohit, Kornhamnstorg 53
111 27 Stockholm, SE | | Representative | | | Opponent | | | IPC Class | A61K 31/4178 (2006.01) , A61K 31/573 (2006.01) , A61K 31/706 (2006.01) , A61K 38/21 (2006.01) , A61K 45/06 (2006.01) , A61P 31/14 (2006.01) | | Title | NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST | | Int. application no. | GB2021050699 | | Int. publication no. | WO2021191592 | | Related patent (certificate) | | | Status | Enhedspatent registreret | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
